BioCentury
ARTICLE | Strategy

Ready to graduate

MEK inhibitor cancer deal with Novartis could be Array's last worldwide deal

April 26, 2010 7:00 AM UTC

Array BioPharma Inc. believes its latest deal could be the last time it out-licenses worldwide rights to assets created by its small molecule discovery and design platform. Last week's deal with Novartis AG, plus a collaboration late last year with Amgen Inc., gave Array co-promotion rights in the U.S., providing the potential to get a sales force on the ground to commercialize its own products.

Array, which has been building its bioinformatics-driven discovery platform since 1998, has 16 compounds in development through partners. But it has nine unpartnered programs, four of which are in the clinic...